\documentclass[journal=jctcce,manuscript=article]{achemso}

%\usepackage{chemformula} 
\usepackage[T1]{fontenc} 
\usepackage{times}
\usepackage{graphicx}
\usepackage{amsmath}
\usepackage{amssymb}
\usepackage{comment}
\usepackage{color}
\usepackage{adjustbox}
\usepackage{multirow}
\usepackage{url}
\usepackage{braket}
\usepackage{textcomp}
\usepackage{threeparttable}
%\usepackage{footnote}
%\makesavenoteenv{tabular}
%\makesavenoteenv{table}


\newcommand{\ham}{\hat{\mathcal{H}}}
\newcommand{\angs}{\AA}
\newcommand{\quotes}[1]{``#1''}
\newcommand{\sm}[1]{\textcolor{blue}{#1}}
\renewcommand{\thepage}{S\arabic{page}}  
\renewcommand{\thesection}{S\arabic{section}}
%\renewcommand{\@makefnmark}{\makebox{\normalfont[\@thefnmark]}}   
\renewcommand{\thetable}{S\arabic{table}}   
\renewcommand{\thefigure}{S\arabic{figure}}

\renewcommand{\thefootnote}{\textit{\alph{footnote}}}

\title{Summary double excitations: state-specific versus state-average opt}

\begin{document}

\section{HNO}
\label{sec:hno}


\begin{table*}[!htb]
\caption{Summary of SA-CASSCF Calculations on HNO}
\resizebox{\columnwidth}{!}{
\begin{threeparttable}
\begin{tabular}{lccrccccrrc}
\hline
CAS/Basis & Manual MO Swaps & MO Types &  No.\ CSFs & \multicolumn{3}{c}{E$_{\rm MCSCF}$} & & \multicolumn{3}{c}{Largest Relevant CSF of ES} \\
\cline{5-7}
\cline{9-11}
        & & & & GS & ES & $\Delta E$ & & No.\ & Coeff. & Occ. of AS \\
\hline
\multicolumn{10}{l}{State-average} \\
CAS(12,9)/BFD-VDZ  & - & \multicolumn{1}{r}{($\sigma_{\rm NO}$,$\sigma_{\rm NH}$,n$_1$,$\pi_{\rm NO}$,n$_2$,n$_3$)-($\pi^*_{\rm NO}$,$\sigma^*_{\rm NH}$,$\sigma^*_{\rm NO}$)} & 1316 & -26.12778 & -25.95578 & 4.6804 & & 42 & 0.943 & \multicolumn{1}{r}{222220\;|\;200} \\
\hline
SA-CASSCF(12,9)/AVDZ & & \multicolumn{1}{c}{all valence orbitals} & & & & \multicolumn{5}{l}{4.70\tnote{a}} \\
SA-CASSCF(12,9)/AVQZ & &  \multicolumn{1}{c}{all valence orbitals} & & & & \multicolumn{5}{l}{4.67\tnote{a}} \\
\hline
\end{tabular}
\begin{tablenotes}
\item[a] Reference~\cite{loos2019}
\end{tablenotes}
\end{threeparttable}}
\label{tab:HNO_cas}
\end{table*}


\begin{table*}[!htb]
\caption{VMC and DMC total energies (a.u.) and excitation energies (eV) of HNO.}
\resizebox{\columnwidth}{!}{
\begin{threeparttable}
\begin{tabular}{lcrrccccccll}
\hline
WF &&  No.\ det & No.\ parm & \multicolumn{2}{c}{E$_{\rm VMC}$} & $\Delta$E$_{\rm VMC}$ & $\tau$ & \multicolumn{2}{c}{E$_{\rm DMC}$} & $\Delta$E$_{\rm DMC}$ \\ 
\cline{5-6}
\cline{9-10}
& & & & GS & ES & & & GS &  ES \\
\hline
\multicolumn{10}{l}{State-average} \\
\cline{1-1}
CAS(12,9)/BFD-VDZ  && 3528 & 1599 & -26.4721(1) & -26.3099(1) & 4.413(4) & 0.0500 & -26.5113(1) & -26.3509(1) & 4.364(4) \\
&& & & & & & 0.0250 & -26.5096(1) & -26.3495(1) & 4.358(4) \\
&& & & & & & 0.0125 & -26.5090(1) & -26.3488(1) & 4.359(5) \\
\multicolumn{10}{l}{State-specific} \\
\cline{1-1}
CAS(2,2)/BFD-VDZ   && 2 & 231 & -26.4462(3) & -26.2764(3) & 4.61(1) & 0.0200&-26.4990(2) & -26.3321(2) & 4.540(6)\\
CAS(12,9)/BFD-VDZ  && 3528 & 1599 & -26.4762(1) & -26.3134(1) & 4.431(5) & 0.0200 & -26.5114(1) & -26.3510(1) & 4.363(4)\\
CIPSI-300/BFD-VDZ  && 301 & 564 & -26.4718(1) & -26.3092(1) & 4.424(7) & 0.0200 & -26.5094(1) &  & \\
CIPSI-1500/BFD-VDZ  && 1521 & 925 & -26.4750(1) & -26.3129(1) & 4.410(6) & 0.0200 & -26.5113(1) & -26.3505(1) & 4.377(2)\\
CIPSI-3000/BFD-VDZ  && 3060 & 1442 & -26.4805(1) & -26.3205(1) & 4.353(6) & 0.0200 & -26.5141(1) & -26.3544(1) & 4.344(2)\\
\hline
\multicolumn{1}{l}{CC3~(\%T$_1$)/aug-cc-pVTZ} && \multicolumn{9}{l}{5.247~(0\%)~\tnote{a}} \\
\multicolumn{1}{l}{CCSDT/aug-cc-pVDZ} && \multicolumn{1}{l}{4.756\tnote{a}} \\
\multicolumn{1}{l}{CC4/aug-cc-pVDZ} && \multicolumn{1}{l}{4.454\tnote{a}} \\
\multicolumn{1}{l}{CCSDTQ/aug-cc-pVDZ} && \multicolumn{1}{l}{4.424\tnote{a}} \\
\multicolumn{1}{l}{FCI/aug-cc-pVDZ} &&  \multicolumn{1}{l}{4.397(1)\tnote{a}} \\
\multicolumn{1}{l}{exFCI/AVDZ} &&  \multicolumn{1}{l}{4.40(1)\tnote{b}} \\
\multicolumn{1}{l}{exFCI/AVQZ} &&  \multicolumn{1}{l}{4.32(0)\tnote{b}} \\
\multicolumn{1}{l}{CASPT2(12,9)/AVDZ} &&  \multicolumn{1}{l}{4.46\tnote{b}} \\
\multicolumn{1}{l}{CASPT2(12,9)/AVQZ} &&  \multicolumn{1}{l}{4.34\tnote{b}} \\
\multicolumn{1}{l}{PC-NEVPT2(12,9)/AVDZ} &&  \multicolumn{1}{l}{4.46\tnote{b}} \\
\multicolumn{1}{l}{PC-NEVPT2(12,9)/AVQZ} &&  \multicolumn{1}{l}{4.35\tnote{b}} \\
\hline
\end{tabular}
\begin{tablenotes}
\item[a] Reference~\cite{loos2021} \item[b] Reference~\cite{loos2019}
\end{tablenotes}
\end{threeparttable}}
\label{tab:hno}
\end{table*}

\clearpage

\begin{figure}[htb]
\begin{center}
\includegraphics[scale=0.5]{HNO-cas129-optimized-orbitals.pdf}
\caption{Optimized NHO orbitals from the SA-CASSCF(12,9)/BFD-VDZ calculation.}
\end{center}
\end{figure}


\clearpage

\section{Glyoxal}
\label{sec:glyoxal}


\begin{table*}[!htb]
\caption{Summary of SA-CASSCF Calculations on Glyoxal}
\resizebox{\columnwidth}{!}{
\begin{threeparttable}
\begin{tabular}{lccrccccrrc}
\hline
CAS/Basis & Manual MO Swaps & MO Types &  No.\ CSFs & \multicolumn{3}{c}{E$_{\rm MCSCF}$} & & \multicolumn{3}{c}{Largest Relevant CSF of ES}\tnote{a} \\
\cline{5-7}
\cline{9-11}
        & & & & GS & ES & $\Delta E$ & & No.\ & Coeff. & Occ. of AS \\
\hline
\multicolumn{10}{l}{State-average} \\
CAS(4,4)/BFD-VDZ   & - & \multicolumn{1}{r}{(n,n)-($\pi^*$,$\pi^*$)} & 8 & -43.73596 & -43.56879 & 4.5490 & & 7 & 0.831 & \multicolumn{1}{r}{20\;|\;20} \\
CAS(8,6)/BFD-VDZ   & - & \multicolumn{1}{r}{($\pi$,$\pi$,n,n)-($\pi^*$,$\pi^*$)} & 33 & -43.81045 & -43.59755 & 5.7933 & & 23 & -0.165 & \multicolumn{1}{r}{2120\;|\;21} \\
CAS(12,8)/BFD-VDZ  & - & \multicolumn{1}{r}{(n,n,$\pi$,$\pi$,n,n)-($\pi^*$,$\pi^*$)} & 96 & -43.81216 & -43.60964 & 5.5109 & & 42 & 0.096 & \multicolumn{1}{r}{122212\;|\;20} \\
CAS(12,8)/BFD-VDZ  & 5$\rightarrow$7\tnote{b} & \multicolumn{1}{r}{(n,n,$\pi$,$\pi$,n,n)-($\pi^*$,$\pi^*$)} & 96 & -43.81216 & -43.60964 & 5.5109 & & 45 & 0.124\tnote{c} & \multicolumn{1}{r}{212221\;|\;20} \\
CAS(12,8)/BFD-VDZ  & 4,5$\rightarrow$6,7\tnote{b} & \multicolumn{1}{r}{(n,n,$\pi$,$\pi$,n,n)-($\pi^*$,$\pi^*$)} & 96 & -43.81216 & -43.60964 & 5.5109 & & 45 & 0.155 & \multicolumn{1}{r}{122221\;|\;20} \\
\hline
SA-CASSCF(8,6)/AVDZ & & \multicolumn{1}{c}{$\pi_{\rm CC}$,$\pi_{\rm CO}$,n$_{\rm O1}$,n$_{\rm O2}$,$\pi^*_{\rm CC}$,$\pi^*_{\rm CO}$} & & & & \multicolumn{5}{l}{5.80\tnote{d}} \\
SA-CASSCF(8,6)/AVQZ & &  \multicolumn{1}{c}{$\pi_{\rm CC}$,$\pi_{\rm CO}$,n$_{\rm O1}$,n$_{\rm O2}$,$\pi^*_{\rm CC}$,$\pi^*_{\rm CO}$} & & & & \multicolumn{5}{l}{5.77\tnote{d}} \\
SA-CASSCF(14,12)/AVDZ & & \multicolumn{1}{c}{$\sigma_{\rm CC}$,$\sigma_{\rm CO}$,$\pi_{\rm CC}$,$\pi_{\rm CO}$,n$_{\rm O1}$,n$_{\rm O2}$,$\pi^*_{\rm CC}$,$\pi^*_{\rm CO}$,$\sigma^*_{\rm CC}$,$\sigma^*_{\rm CO}$} & & & & \multicolumn{5}{l}{5.94\tnote{d}} \\
SA-CASSCF(14,12)AVQZ & & \multicolumn{1}{c}{$\sigma_{\rm CC}$,$\sigma_{\rm CO}$,$\pi_{\rm CC}$,$\pi_{\rm CO}$,n$_{\rm O1}$,n$_{\rm O2}$,$\pi^*_{\rm CC}$,$\pi^*_{\rm CO}$,$\sigma^*_{\rm CC}$,$\sigma^*_{\rm CO}$} & & & & \multicolumn{5}{l}{5.92\tnote{d}} \\
\hline
\end{tabular}
\begin{tablenotes}
\item[a] This refers to only configurations (of ES / State 2) with excitations of orbitals added to the active space of the prevous CAS. This column only makes sense to include if the CAS's are run in which the active space is increased. \item[b] Orbitals swapped back despite manual swap. \item[c] All CAS(12,8) runs have essentially the same energy yet the csf coefficients appear pretty different. Are the values comparable (not normalized)? In any case shouldn't the same csf be the largest? \item[d] Reference~\cite{loos2019}
\end{tablenotes}
\end{threeparttable}}
\label{tab:glyoxalcas}
\end{table*}


\begin{table*}[!htb]
\caption{VMC and DMC total energies (a.u.) and excitation energies (eV) of Glyoxal.}
\resizebox{\columnwidth}{!}{
\begin{threeparttable}
\begin{tabular}{lcrrccccccll}
\hline
WF &&  No.\ det & No.\ parm & \multicolumn{2}{c}{E$_{\rm VMC}$} & $\Delta$E$_{\rm VMC}$ & $\tau$ & \multicolumn{2}{c}{E$_{\rm DMC}$} & $\Delta$E$_{\rm DMC}$ \\
\cline{5-6}
\cline{9-10}
& & & & GS & ES & & & GS &  ES \\
\hline
\multicolumn{10}{l}{State-average} \\
\cline{1-1}
CAS(8,6)/BFD-VDZ  &&   61 &  441 & -44.5545(2) & -44.3430(2) & 5.755(7) & 0.05 & -44.6410(2) & -44.4314(2) & 5.704(6) \\
CAS(12,8)/BFD-VDZ &&  208 &  507 & -44.5563(2) & -44.3482(2) & 5.662(7) & 0.05 & -44.6422(2) & -44.4341(2) & 5.663(6) \\
\multicolumn{10}{l}{State-specific} \\
\cline{1-1}
CAS(8,6)/BFD-VDZ  &&  61 & 441 & -44.5600(1) & -44.3460(1) & 5.823(5) & 0.05 & -44.6445(16) & -44.4325(16) & 5.768(6) \\
CAS(12,8)/BFD-VDZ && 208 & 506 & -44.5611(2) & -44.3510(2) & 5.717(8) & 0.02 & -44.6425(1) & -44.4339(1) & 5.676(4) \\ 
\hline
\multicolumn{1}{l}{exFCI/AVDZ} &&  \multicolumn{1}{l}{5.48(0)\tnote{a}} \\
\multicolumn{1}{l}{CC3 (\%T$_1$)/AVQZ} &&  \multicolumn{1}{l}{6.76 (1\%)\tnote{a}} \\
\multicolumn{1}{l}{CASPT2(8,6)/AVDZ} &&  \multicolumn{1}{l}{5.55\tnote{a}} \\
\multicolumn{1}{l}{CASPT2(8,6)/AVQZ} &&  \multicolumn{1}{l}{5.52\tnote{a}} \\
\multicolumn{1}{l}{CASPT2(14,12)/AVDZ} &&  \multicolumn{1}{l}{5.47\tnote{a}} \\
\multicolumn{1}{l}{CASPT2(14,12)/AVQZ} &&  \multicolumn{1}{l}{5.43\tnote{a}} \\
\multicolumn{1}{l}{PC-NEVPT2(14,12)/AVDZ} &&  \multicolumn{1}{l}{5.56\tnote{a}} \\
\multicolumn{1}{l}{PC-NEVPT2(14,12)/AVQZ} &&  \multicolumn{1}{l}{5.52\tnote{a}} \\
\multicolumn{1}{l}{SC-NEVPT2(14,12)/AVDZ} &&  \multicolumn{1}{l}{5.58\tnote{a}} \\
\multicolumn{1}{l}{SC-NEVPT2(14,12)/AVQZ} &&  \multicolumn{1}{l}{5.55\tnote{a}} \\
\hline
\end{tabular}
\begin{tablenotes}
\item[a] Reference~\cite{loos2019}
\end{tablenotes}
\end{threeparttable}}
\label{tab:glyoxal}
\end{table*}



\clearpage


\begin{figure}[htb]
\begin{center}
\includegraphics[scale=0.5]{glyoxal-cas86-opt-orbitals.pdf}
\caption{Optimized glyoxal orbitals from the SA-CASSCF(8,6)/BFD-VDZ calculation.}
\end{center}
\end{figure}

\clearpage

\begin{figure}[htb]
\begin{center}
\includegraphics[scale=0.5]{glyoxal-cas128-comparison-opt-orbitals.pdf}
\caption{Comparison of optimized glyoxal orbitals from the SA-CASSCF(12,8)/BFD-VDZ calculation to the SA-CASSCF(8,6)/BFD-VDZ calculation which show change in character or possibly rearranged. The two orbitals in the red box are added to the CAS(8,6) orbitals to make the CAS(12,8) active space. Orbitals 1-3 and 8-13 appear the same and stay in the same order in both.}
\end{center}
\end{figure}


\clearpage

\section{Tetrazine}
\label{sec:tetrazine}


\begin{table*}[!htb]
\caption{Summary of CASSCF Calculations on Tetrazine (1$^1A_{1g}\rightarrow$2$^1A_{1g}$)}
\resizebox{\columnwidth}{!}{
\begin{threeparttable}
\begin{tabular}{lccrccccrrc}
\hline
CAS/Basis & Manual MO Swaps & MO Types &  No.\ CSFs & \multicolumn{3}{c}{E$_{\rm MCSCF}$} & & \multicolumn{3}{c}{Largest Relevant CSF of ES} \\
\cline{5-7}
\cline{9-11}
        & & & & GS & ES & $\Delta E$ & & No.\ & Coeff. & Occ. of AS \\
\hline
\multicolumn{10}{l}{State-average} \\
CAS(4,4)/BFD-VDZ  & - & \multicolumn{1}{r}{(n$_3$,n$_4$)-($\pi^*_4$,$\pi^*_5$)\;\;\;\;\;} & 6 & -51.02881 & -50.80697 & 6.037 & & 2 & 0.899 & \multicolumn{1}{r}{20 | 20 \;} \\
CAS(8,6)/BFD-VDZ  & - & \multicolumn{1}{r}{($\pi_2$,n$_3$,$\pi_3$,n$_4$)-($\pi^*_4$,$\pi^*_5$)\;\;\;\;\;} & 21 & -51.07941 & -50.82163 & 7.015 & & 5 & -0.382 & \multicolumn{1}{r}{2202 | 20 \;} \\
CAS(12,8)/BFD-VDZ  & - & \multicolumn{1}{r}{(n$_1$,n$_2$,$\pi_2$,n$_3$,$\pi_3$,n$_4$)-($\pi^*_4$,$\pi^*_5$)\;\;\;\;\;} & 56 & -51.07999 & -50.84678 & 6.346 & & 42 & -0.188 & \multicolumn{1}{r}{022222 | 20 \;} \\
CAS(14,10)/BFD-VDZ  & 38$\rightarrow$18\tnote{a} & \multicolumn{1}{r}{($\pi_1$,n$_1$,n$_2$,$\pi_2$,n$_3$,$\pi_3$,n$_4$)-($\pi^*_4$,$\pi^*_5$,$\pi^*_6$)} & 670 & -51.13015 & -50.93001 & 5.446 & & 14 & 0.162 & \multicolumn{1}{r}{2222121 | 101} \\
\hline
SA-CASSCF(14,10)/AVDZ & & \multicolumn{1}{c}{$\pi$ valence space (6), (4) n$_{\rm N}$ on nitrogen atoms} & & & & \multicolumn{5}{l}{5.48\tnote{b}} \\
SA-CASSCF(14,10)/AVQZ & & \multicolumn{1}{c}{$\pi$ valence space (6), (4) n$_{\rm N}$ on nitrogen atoms} & & & & \multicolumn{5}{l}{5.41\tnote{b}} \\
\hline
\end{tabular}
\begin{tablenotes}
\item[a] To include highest $\pi^*$ orbital. Swap held. \item[b] Reference~\cite{loos2019}
\end{tablenotes}
\end{threeparttable}}
\label{tab:tetrazine_cas}
\end{table*}




\begin{table*}[!htb]
\caption{VMC and DMC total energies (a.u.) and excitation energies (eV) of Tetrazine.}

\resizebox{\columnwidth}{!}{
\begin{threeparttable}
\begin{tabular}{lcrrccccccll}
\hline
WF &&  No.\ det & No.\ parm & \multicolumn{2}{c}{E$_{\rm VMC}$} & $\Delta$E$_{\rm VMC}$ & $\tau$ & \multicolumn{2}{c}{E$_{\rm DMC}$} & $\Delta$E$_{\rm DMC}$ \\
\cline{5-6}
\cline{9-10}
& & & & GS & ES & & & GS &  ES \\
\hline
\multicolumn{10}{l}{State-average} \\
\cline{1-1} 
CAS(4,4)/BFD-VDZ  &&    6 &  400 & -52.1496(6) & -51.9507(6) & 5.41(2) & 0.05 & -52.2647(2) & -52.0744(2) & 5.179(7) \\
CAS(8,6)/BFD-VDZ  &&   33 &  415 & -52.1627(7) & -51.9550(7) & 5.65(3) & 0.05 & -52.2728(2) & -52.0769(2) & 5.332(7) \\
CAS(12,8)/BFD-VDZ &&  112 &  455 & -52.1643(6) & -51.9644(6) & 5.44(2) & 0.05 & -52.2738(2) & -52.0828(2) & 5.196(7) \\
CAS(14,10)/BFD-VDZ && 1824 & 1139 & -52.1732(1) & -51.9840(1) & 5.148(5) & 0.05 & -52.2784(2) & -52.0922(2) & 5.067(7) \\
\multicolumn{10}{l}{State-specific} \\
\cline{1-1}
CAS(14,10)/BFD-VDZ && 1824 & 1078 & -52.1778(2) & -51.9887(2) & 5.147(9) & 0.02 & -52.2805(1) & -52.0941(1) & 5.071(4)\\
\hline
\multicolumn{1}{l}{CCSDT/AVDZ} &&  \multicolumn{9}{l}{5.86\tnote{a}} \\
\multicolumn{1}{l}{CC3~(\%T$_1$)/AVDZ} &&  \multicolumn{9}{l}{6.22~(1\%)\tnote{a}} \\
\multicolumn{1}{l}{CC3~(\%T$_1$)/AVQZ} &&  \multicolumn{9}{l}{6.19~(1\%)\tnote{a}} \\
\multicolumn{1}{l}{CASPT2(14,10)/AVDZ} &&  \multicolumn{9}{l}{4.79\tnote{a}} \\
\multicolumn{1}{l}{CASPT2(14,10)/AVQZ} &&  \multicolumn{9}{l}{4.68\tnote{a}} \\
\multicolumn{1}{l}{PC-NEVPT2(14,10)/AVDZ} &&  \multicolumn{9}{l}{4.70\tnote{a}} \\
\multicolumn{1}{l}{PC-NEVPT2(14,10)/AVQZ} &&  \multicolumn{9}{l}{4.60\tnote{a}} \\
\multicolumn{1}{l}{SC-NEVPT2(14,10)/AVDZ} &&  \multicolumn{9}{l}{4.78\tnote{a}} \\
\multicolumn{1}{l}{SC-NEVPT2(14,10)/AVQZ} &&  \multicolumn{9}{l}{4.68\tnote{a}} \\
\hline
\end{tabular}
\begin{tablenotes}
\item[a] Reference~\cite{loos2019}
\end{tablenotes}
\end{threeparttable}}
\label{tab:tetrazine}
\end{table*}

\clearpage

\begin{figure}[htb]
\begin{center}
\includegraphics[scale=0.5]{tetrazine_cas-1410-opt-orbs.pdf}
\caption{Optimized tetrazine orbitals from the SA-CASSCF(14,10)/BFD-VDZ calculation.}
\end{center}
\end{figure}

\clearpage


\bibliographystyle{unsrt}
\bibliography{summary.bib}

\end{document}
